An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease.
Humans
Female
Male
tau Proteins
/ cerebrospinal fluid
Glial Fibrillary Acidic Protein
/ cerebrospinal fluid
Middle Aged
Neurofilament Proteins
/ cerebrospinal fluid
Biomarkers
/ cerebrospinal fluid
Adult
Mental Disorders
/ cerebrospinal fluid
Autoimmune Diseases
/ cerebrospinal fluid
Magnetic Resonance Imaging
Cohort Studies
Aged
Electroencephalography
Autoantibodies
/ cerebrospinal fluid
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
25
10
2023
accepted:
10
07
2024
revised:
27
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
24
7
2024
Statut:
epublish
Résumé
There is growing evidence suggesting that immunological mechanisms play a significant role in the development of psychiatric symptoms in certain patient subgroups. However, the relationship between clinical red flags for suspected autoimmune psychiatric disease and signs of central nervous system (CNS) pathology (e.g., routine cerebrospinal fluid (CSF) alterations, CNS damage markers, neurophysiological or neuroimaging findings) has received limited attention. Here, we aimed to describe the prevalence and distribution of potential CNS pathologies in psychiatric patients in relation to clinical red flags for autoimmune psychiatric disease and psychiatric symptoms. CSF routine findings and CNS damage markers; neurofilament light chain protein (NfL), glial fibrillary acidic protein (GFAP) and total Tau (t-Tau), in CSF from 127 patients with psychiatric disease preselected for suspected immunological involvement were related to recently proposed clinical red flags, psychiatric features, and MRI and EEG findings. Twenty-one percent had abnormal routine CSF findings and 27% had elevated levels of CNS damage markers. Six percent had anti-neuronal antibodies in serum and 2% had these antibodies in the CSF. Sixty-six percent of patients examined with MRI (n = 88) had alterations, mostly atrophy or nonspecific white matter lesions. Twenty-seven percent of patients with EEG recordings (n = 70) had abnormal findings. Elevated NfL levels were associated with comorbid autoimmunity and affective dysregulation symptoms. Elevated t-Tau was associated with catatonia and higher ratings of agitation/hyperactivity. Elevated GFAP was associated with acute onset, atypical presentation, infectious prodrome, tics, depressive/anxiety symptom ratings and overall greater psychiatric symptom burden. In conclusion, preselection based on suspected autoimmune psychiatric disease identifies a population with a high prevalence of CSF alterations suggesting CNS pathology. Future studies should examine the value of these markers in predicting treatment responses.
Identifiants
pubmed: 39048548
doi: 10.1038/s41398-024-03021-8
pii: 10.1038/s41398-024-03021-8
doi:
Substances chimiques
tau Proteins
0
Glial Fibrillary Acidic Protein
0
neurofilament protein L
0
Neurofilament Proteins
0
Biomarkers
0
GFAP protein, human
0
MAPT protein, human
0
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
304Informations de copyright
© 2024. The Author(s).
Références
Muller N, Wagner JK, Krause D, Weidinger E, Wildenauer A, Obermeier M, et al. Impaired monocyte activation in schizophrenia. Psychiatry Res. 2012;198:341–6.
pubmed: 22429483
doi: 10.1016/j.psychres.2011.12.049
Tiosano S, Farhi A, Watad A, Grysman N, Stryjer R, Amital H, et al. Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study. Epidemiol Psychiatr Sci. 2017;26:424–9.
pubmed: 27457404
doi: 10.1017/S2045796016000561
Sloan M, Wincup C, Harwood R, Pollak TA, Massou E, Bosley M, et al. Prevalence and identification of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases: an international mixed methods study. Rheumatology. 2023;63:1259–72.
Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol Psychiatr Sci. 2019;28:333–42.
pubmed: 29098977
doi: 10.1017/S2045796017000579
Wittenberg GM, Stylianou A, Zhang Y, Sun Y, Gupta A, Jagannatha PS, et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol Psychiatry. 2020;25:1275–85.
pubmed: 31427751
doi: 10.1038/s41380-019-0471-8
Pollak TA, Lennox BR, Muller S, Benros ME, Pruss H, Tebartz van Elst L, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020;7:93–108.
pubmed: 31669058
doi: 10.1016/S2215-0366(19)30290-1
Endres D, Pollak TA, Bechter K, et al. Immunological causes of obsessive-compulsive disorder: is it time for the concept of an “autoimmune OCD” subtype? Transl Psychiatry. 2022;12:5
pubmed: 35013105
pmcid: 8744027
doi: 10.1038/s41398-021-01700-4
Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
doi: 10.1038/nature13595
Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177–83.
pubmed: 26814963
pmcid: 4752392
doi: 10.1038/nature16549
Trubetskoy V, Pardinas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604:502–8.
pubmed: 35396580
pmcid: 9392466
doi: 10.1038/s41586-022-04434-5
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663–71.
pubmed: 21641581
pmcid: 4071300
doi: 10.1016/j.biopsych.2011.04.013
Khandaker GM, Dantzer R, Jones PB. Immunopsychiatry: important facts. Psychol Med. 2017;47:2229–37.
pubmed: 28418288
pmcid: 5817424
doi: 10.1017/S0033291717000745
Gerentes M, Pelissolo A, Rajagopal K, Tamouza R, Hamdani N. Obsessive-compulsive disorder: autoimmunity and neuroinflammation. Curr Psychiatry Rep. 2019;21:78.
pubmed: 31367805
doi: 10.1007/s11920-019-1062-8
Kohler-Forsberg O, Petersen L, Gasse C, Mortensen PB, Dalsgaard S, Yolken RH, et al. A nationwide study in denmark of the association between treated infections and the subsequent risk of treated mental disorders in children and adolescents. JAMA Psychiatry. 2019;76:271–9.
pubmed: 30516814
doi: 10.1001/jamapsychiatry.2018.3428
Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97:839–87.
pubmed: 28298428
pmcid: 5539405
doi: 10.1152/physrev.00010.2016
Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann NY Acad Sci. 2015;1338:94–114.
pubmed: 25315420
doi: 10.1111/nyas.12553
Dalmau J, Graus F. Antibody-mediated encephalitis. N. Engl J Med. 2018;378:840–51.
pubmed: 29490181
doi: 10.1056/NEJMra1708712
Platt MP, Agalliu D, Cutforth T. Hello from the other side: how autoantibodies circumvent the blood–brain barrier in autoimmune encephalitis. Front Immunol. 2017;8:442.
pubmed: 28484451
pmcid: 5399040
doi: 10.3389/fimmu.2017.00442
Herken J, Pruss H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry. 2017;8:25.
pubmed: 28261116
pmcid: 5311041
doi: 10.3389/fpsyt.2017.00025
Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.
pubmed: 23290630
pmcid: 3563251
doi: 10.1016/S1474-4422(12)70310-1
Endres D, Maier V, Leypoldt F, Wandinger KP, Lennox B, Pollak TA, et al. Autoantibody-associated psychiatric syndromes: a systematic literature review resulting in 145 cases. Psychol Med. 2020:52:1135–46.
Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci. 2011;23:90–97.
pubmed: 21304144
pmcid: 3086677
doi: 10.1176/appi.neuropsych.23.1.90
Endres D, Meixensberger S, Dersch R, Feige B, Stich O, Venhoff N, et al. Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Transl Psychiatry. 2020;10:279.
pubmed: 32782247
pmcid: 7419532
doi: 10.1038/s41398-020-00967-3
Guasp M, Gine-Serven E, Maudes E, Rosa-Justicia M, Martinez-Hernandez E, Boix-Quintana E, et al. Clinical, neuroimmunologic, and CSF investigations in first episode psychosis. Neurology. 2021;97:e61–e75.
pubmed: 33980703
doi: 10.1212/WNL.0000000000012191
Najjar S, Steiner J, Najjar A, Bechter K. A clinical approach to new-onset psychosis associated with immune dysregulation: the concept of autoimmune psychosis. J Neuroinflamm. 2018;15:40.
doi: 10.1186/s12974-018-1067-y
Ellul P, Groc L, Tamouza R, Leboyer M. The clinical challenge of autoimmune psychosis: learning from anti-NMDA receptor autoantibodies. Front Psychiatry. 2017;8:54.
pubmed: 28469581
pmcid: 5396186
doi: 10.3389/fpsyt.2017.00054
Middeldorp J, Hol EM. GFAP in health and disease. Prog Neurobiol. 2011;93:421–43.
pubmed: 21219963
doi: 10.1016/j.pneurobio.2011.01.005
Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870–81.
pubmed: 30967444
doi: 10.1136/jnnp-2018-320106
Zetterberg H. Review: Tau in biofluids—relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol. 2017;43:194–9.
pubmed: 28054371
doi: 10.1111/nan.12378
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.
pubmed: 20157306
doi: 10.1038/nrneurol.2010.4
Kortvelyessy P, Pruss H, Thurner L, Maetzler W, Vittore-Welliong D, Schultze-Amberger J, et al. Biomarkers of neurodegeneration in autoimmune-mediated encephalitis. Front Neurol. 2018;9:668.
pubmed: 30283395
pmcid: 6156245
doi: 10.3389/fneur.2018.00668
Guasp M, Martin-Aguilar L, Sabater L, Bioque M, Armangue T, Martinez-Hernandez E, et al. Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis. Neurology. 2022;98:e1489–e1498.
pubmed: 35145006
doi: 10.1212/WNL.0000000000200021
Cunningham JL, Nordmark G, Fällmar D, Cervenka S, Gallwitz M, Säll R, et al. Experiences in implementing immunopsychiatry in real life. J Affect Disord Rep. 2023;13:100597.
doi: 10.1016/j.jadr.2023.100597
Bush G, Fink M, Petrides G, Dowling F, Francis A. Catatonia I. Rating scale and standardized. Acta Psychiatr Scand. 1996;93:129-36.
Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale–Expanded (BPRS-E) structure and arguments for a new version. J Psychiatr Res. 2016;81:140–51.
pubmed: 27451107
doi: 10.1016/j.jpsychires.2016.07.001
Ungvari GS, Goggins W, Leung S-K, Gerevich J. Schizophrenia with prominent catatonic features (‘catatonic schizophrenia’). II. Factor analysis of the catatonic syndrome. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31:462–8.
doi: 10.1016/j.pnpbp.2006.11.012
Velligan D, Prihoda T, Dennehy E, Biggs M, Shores-Wilson K, Crismon ML, et al. Brief psychiatric rating scale expanded version: how do new items affect factor structure? Psychiatry Res. 2005;135:217–28.
pubmed: 15993949
doi: 10.1016/j.psychres.2005.05.001
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007;4:28.
pubmed: 20526405
pmcid: 2880930
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.
pubmed: 26906964
pmcid: 5066574
doi: 10.1016/S1474-4422(15)00401-9
Gaetani L, Hoglund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P, et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018;10:8.
pubmed: 29370869
pmcid: 6389166
doi: 10.1186/s13195-018-0339-1
Rosengren LE, Ahlsen G, Belfrage M, Gillberg C, Haglid KG, Hamberger A. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of children. J Neurosci Methods. 1992;44:113–9.
pubmed: 1474847
doi: 10.1016/0165-0270(92)90004-W
Fazekas F, Barkhof F, Wahlund LO, Pantoni L, Erkinjuntti T, Scheltens P, et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis. 2002;13:31–36.
pubmed: 11901240
doi: 10.1159/000049147
Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967–72.
pubmed: 1431963
pmcid: 1015202
doi: 10.1136/jnnp.55.10.967
Breiman L. Random forests. Mach Learn. 2001;45:5–32.
doi: 10.1023/A:1010933404324
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
pubmed: 9324032
doi: 10.1002/art.1780400928
Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003;987:25–31.
pubmed: 14499942
doi: 10.1016/S0006-8993(03)03219-0
Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology. 2006;67:1600–4.
pubmed: 17101890
doi: 10.1212/01.wnl.0000242732.06714.0f
Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48:2881–7.
pubmed: 14558094
doi: 10.1002/art.11279
Tjensvoll AB, Lauvsnes MB, Zetterberg H, Kvaloy JT, Kvivik I, Maroni SS, et al. Neurofilament light is a biomarker of brain involvement in lupus and primary Sjogren’s syndrome. J Neurol. 2021;268:1385–94.
pubmed: 33128084
doi: 10.1007/s00415-020-10290-y
Levine J, Kwon E, Paez P, Yan W, Czerwieniec G, Loo JA, et al. Traumatically injured astrocytes release a proteomic signature modulated by STAT3-dependent cell survival. Glia. 2016;64:668–94.
pubmed: 26683444
doi: 10.1002/glia.22953
Kumar A, Fontana IC, Nordberg A. Reactive astrogliosis: a friend or foe in the pathogenesis of Alzheimer’s disease. J Neurochem. 2023;164:309–24.
pubmed: 34931315
doi: 10.1111/jnc.15565
Pekny M, Pekna M. Reactive gliosis in the pathogenesis of CNS diseases. Biochim Biophys Acta. 2016;1862:483–91.
pubmed: 26655603
doi: 10.1016/j.bbadis.2015.11.014
Soung A, Klein RS. Viral encephalitis and neurologic diseases: focus on astrocytes. Trends Mol Med. 2018;24:950–62.
pubmed: 30314877
pmcid: 6546292
doi: 10.1016/j.molmed.2018.09.001
Abdelhak A, Hottenrott T, Morenas-Rodriguez E, Suarez-Calvet M, Zettl UK, Haass C, et al. Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? Front Neurol. 2019;10:280.
pubmed: 30972011
pmcid: 6443875
doi: 10.3389/fneur.2019.00280
Michel M, Fiebich BL, Kuzior H, Meixensberger S, Berger B, Maier S, et al. Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. Transl Psychiatry. 2021;11:308.
pubmed: 34021122
pmcid: 8139962
doi: 10.1038/s41398-021-01423-6
Lynch DR, Rattelle A, Dong YN, Roslin K, Gleichman AJ, Panzer JA. Anti-NMDA receptor encephalitis: clinical features and basic mechanisms. Adv Pharm. 2018;82:235–60.
doi: 10.1016/bs.apha.2017.08.005
Johnson M, Fernell E, Gillberg C, Fasth A, Dinkler L, Blennow K, et al. No neurochemical evidence of neuronal injury or glial activation in children with paediatric acute-onset neuropsychiatric syndrome. An explorative pilot study. The World J Biol Psychiatry. 2021;22:800–4.
Kim KW, MacFall JR, Payne ME. Classification of white matter lesions on magnetic resonance imaging in elderly persons. Biol Psychiatry. 2008;64:273–80.
pubmed: 18471801
pmcid: 2593803
doi: 10.1016/j.biopsych.2008.03.024
Blackman G, Neri G, Al-Doori O, Teixeira-Dias M, Mazumder A, Pollak TA. et al. Prevalence of neuroradiological abnormalities in first-episode psychosis: a systematic review and meta-analysis. JAMA Psychiatry. 2023;80:1047–54.
pubmed: 37436735
pmcid: 10339221
doi: 10.1001/jamapsychiatry.2023.2225
O’Sullivan S, Mullins G, Cassidy E, McNamara B. The role of the standard EEG in clinical psychiatry. Hum Psychopharmacol: Clin Exp. 2006;21:265–71.
doi: 10.1002/hup.767
Kaplan PW, Rossetti AO. EEG patterns and imaging correlations in encephalopathy: encephalopathy part II. J Clin Neurophysiol. 2011;28:233–51.
pubmed: 21633250
doi: 10.1097/WNP.0b013e31821c33a0
Milikovsky DZ, Ofer J, Senatorov VV Jr, Friedman AR, Prager O, Sheintuch L, et al. Paroxysmal slow cortical activity in Alzheimer’s disease and epilepsy is associated with blood-brain barrier dysfunction. Sci Transl Med. 2019;11:eaaw8954.
pubmed: 31801888
doi: 10.1126/scitranslmed.aaw8954
Rattay TW, Martin P, Vittore D, Hengel H, Cebi I, Tünnerhoff J. et al. Cerebrospinal fluid findings in patients with psychotic symptoms—a retrospective analysis. Sci Rep.2021;11:1–12.
doi: 10.1038/s41598-021-86170-w
Bien CG, Rohleder C, Mueller JK, Bien CI, Koethe D, Leweke FM. Neural autoantibodies in cerebrospinal fluid and serum in clinical high risk for psychosis, first-episode psychosis, and healthy volunteers. Front Psychiatry. 2021;12:382.
doi: 10.3389/fpsyt.2021.654602
Theorell J, Ramberger M, Harrison R, Mgbachi V, Jacobson L, Waters P, et al. Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis. Transl Psychiatry. 2021;11:566.
pubmed: 34741015
pmcid: 8571405
doi: 10.1038/s41398-021-01701-3
Cullen AE, Palmer-Cooper EC, Hardwick M, Vaggers S, Crowley H, Pollak TA, et al. Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-analysis of cross-sectional and case-control studies. Lancet Psychiatry. 2021;8:109–20.
pubmed: 33357497
doi: 10.1016/S2215-0366(20)30432-6
Theorell J, Ramberger M, Harrison R, Mgbachi V, Jacobson L, Waters P, et al. Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis. Transl Psychiatry. 2021;11:1–7.
doi: 10.1038/s41398-021-01701-3
Mulder J, Feresiadou A, Fällmar D, Frithiof R, Virhammar J, Rasmusson A, et al. Autoimmune encephalitis presenting with malignant catatonia in a 40-year-old male patient with Covid-19. Am J Psychiatry. 2021;178:485–9.
pubmed: 34154381
doi: 10.1176/appi.ajp.2020.20081236
Sloan M, Harwood R, Sutton S, D’Cruz D, Howard P, Wincup C, et al. Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatol Adv Pr. 2020;4:rkaa006.
doi: 10.1093/rap/rkaa006
Govoni M, Hanly JG. The management of neuropsychiatric lupus in the 21st century: still so many unmet needs? Rheumatology. 2020;59:v52–v62.
pubmed: 33280014
pmcid: 7719041
doi: 10.1093/rheumatology/keaa404
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45.
pubmed: 30926722
doi: 10.1136/annrheumdis-2019-215089